TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18923838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (i.v. corticosteroids: methylprednisolon 250 mg for 3 days and tapering to zero, or i.v. hemodilution: 500 mL 6% hydroxyethyl starch plus 600 mg pentoxifylline per day for 10 days)
Study: 16583215
Drug: Gd-DTPA contrast
Normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-DTPA contrast agent during bolus administration
Study: 3629090
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg arecoline
Study: 3549875
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg glycopyrrolate
Study: 29324401
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine monotherapy (CBZ-CR)
Study: 29324401
Drug: Lamotrigine and
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine and valproate combination therapy (LTG+VPA)
Study: 21254378
Drug: Initial lumbar
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial lumbar puncture on day 8 in remission induction therapy
Study: 20354750
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenous monthly for 6 months)
Study: 18048433
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg/day for 1 week)
Study: 27922020
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg every other day (EOD), once a morning (OM)
Study: 27922020
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive pharmacotherapy
Study: 23807278
Drug: 12 ml
Normalized name: syringe, disposable, 12 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml of 0.5 % bupivacaine plus 150 mg magnesium sulphate (in 3 ml 0.9 % saline)
Study: 6428120
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + glibenclamide
Study: 6428120
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + placebo
Study: 6972513
Drug: Hydrocortisone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (12.5 mg/kg, two doses on the first day of life)
Study: 29093180
Drug: Rozanolixizumab (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab (IV or SC) at doses of 1, 4, or 7 mg/kg
Study: 29093180
Drug: Rozanolixizumab (highest-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab (highest-dose IV group)
Study: 25870986
Drug: ART12 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART12 (12 weeks of antiretroviral therapy)
Study: 25870986
Drug: ART48 (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART48 (48 weeks of antiretroviral therapy)
Study: 15012784
Drug: No pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pancreatic enzyme replacement therapy (no PERT)
Study: 31811682
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) treatment
Study: 9601155
Drug: Proctoclysis (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proctoclysis (rectal hydration) with normal saline or tap water at a rate of 250 +/- 63 cc/hr for 15 +/- 8 days
Study: 30702488
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg) plus Lansoprazole (30 mg daily)
Study: 30702488
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Lansoprazole (30 mg daily)
Study: 25525195
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of darunavir (DRV600) once daily
Study: 25525195
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of darunavir (DRV800) once daily
Study: 21729811
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg/kg (Group L)
Study: 21729811
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg/kg‐ephedrine 30 μg/kg (Group LE)
Study: 21729811
Drug: Ephedrine 30
Normalized name: ephedrine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 30 μg/kg (Group E30)
Study: 21729811
Drug: Ephedrine 70
Normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 70 μg/kg (Group E70)
Study: 17121171
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders
Study: 15371138
Drug: Interferon-based therapies
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-based therapies
Study: 10217581
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg of alum-precipitated mAb 13B8.2
Study: 7618705
Drug: Esmolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (300 micrograms.kg‐1.min‐1 during CPB after bolus of 2 mg/kg prior to CPB)
Study: 18549515
Drug: Active rehabilitation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rehabilitation (group R) - 10 sessions including exercises on a stabilometric platform, point de mire, and a series of five exercises repeated five times daily.
Study: 18549515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) - told to 'perform their daily activities'.
Study: 14756468
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 2 weeks
Study: 14756468
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg and montelukast 10 mg once daily for 2 weeks
Study: 11294481
Drug: Sertraline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-150 mg for nortriptyline comparator trial; 50-100 mg for fluoxetine comparator trial)
Study: 9021962
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-n3 lower doses (1.0, 2.5, 5.0 MU)
Study: 29370144
Drug: Whey Proteins
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Proteins (WP) pre-meal (20 g)
Study: 25514542
Drug: MPH-MLR 80
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH-MLR 80 mg capsule or sprinkles
Study: 25514542
Drug: Ritalin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin IR 25 mg
Study: 15570920
Drug: CPT-11 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 with CDDP therapy
Study: 10772604
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day naltrexone
Study: 9310275
Drug: Bisoprolol once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol once daily for 8 weeks
Study: 9310275
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard twice daily for 8 weeks
Study: 17852760
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation treatment (25 hours, across 8 weeks)
Study: 26849844
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/day)
Study: 7502516
Drug: ACE-inhibitor Cilacapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor Cilacapril, taken once a day between 7.00 a.m. and 9.00 a.m.
Study: 1953094
Drug: Glutamine-enriched intravenous
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched intravenous feedings (0.57 g/kg/day, GLN)
Study: 1953094
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (STD)
Study: 7010893
Drug: Heparin, 5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, 5000 units every 8 hours for 14 days
Study: 7010893
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as soon as possible after the fracture
Study: 28610932
Drug: Manual disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual disinfection with 0.5% sodium hypochlorite solution
Study: 23393182
Drug: Insulin-resistant individuals
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant individuals
Study: 23393182
Drug: Insulin-sensitive individuals
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive individuals
Study: 21542027
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg dose of alcohol (cumulative dose 0.8 g/kg)
Study: 9260367
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (5-10 mg daily, doubled if necessary)
Study: 9260367
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg daily, doubled if necessary)
Study: 8294169
Drug: Netilmicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (100 mg dose)
Study: 2832287
Drug: Cyproheptadine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (0.1 mg/kg body weight)
Study: 29943054
Drug: Laparoscopic-guided TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-guided TAP block with 20 ml of 0.25% bupivacaine
Study: 29943054
Drug: Standard port
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard port site infiltration with 3-5 ml of 0.25% bupivacaine
Study: 27994001
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg folic acid/day for 90 days
Study: 25711262
Drug: i‐gel® (i‐gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i‐gel® (i‐gel)
Study: 23547511
Drug: Platelet Rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Rich Fibrin (PRF) applied locally (6 ml)
Study: 19655334
Drug: Polygeline infusion
Normalized name: polygeline
DrugBank: Polygeline (DB15879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygeline infusion
Study: 11872276
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after surgery until tumor progression (Control)
Study: 9672056
Drug: Pharmacotherapy (nortriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (nortriptyline hydrochloride)
Study: 9672056
Drug: Pharmacotherapy relative
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy relative to usual care
Study: 7601178
Drug: Topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID felbinac
Study: 7601178
Drug: Oral NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NSAIDs (ibuprofen, fenbufen)
Study: 28737627
Drug: PHiD‐CV10 (10-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV10 (10-valent pneumococcal conjugate vaccine)
Study: 23283428
Drug: Simvastatin 3
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 3 mg/kg
Study: 14987187
Drug: Head-down tilt
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-down tilt position during physiotherapy treatment
Study: 14987187
Drug: Flat side-lying
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat side-lying position during physiotherapy treatment
Study: 14987187
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment (both positions)
Study: 9040032
Drug: Adenosine receptor
Normalized name: Adenosine receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine receptor stimulation (ADO) trabeculae, 125 micromol/l for 5 min
Study: 9040032
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of K(ATP) channel with glibenclamide (GLI) trabeculae, 10 micromol/l
Study: 8164027
Drug: GM2/BCG vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM2/BCG vaccine
Study: 2500069
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 mg of MMC on the day of surgery and 10 mg of MMC the day after surgery, started on tegafur at a dose of 600 mg/day 2 weeks after surgery
Study: 2500069
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: similarly treated with MMC and started on UFT at a dose of 600 mg/day 2 weeks after surgery
Study: 1101081
Drug: Vincristine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine and Prednisone reinduction therapy
Study: 22821424
Drug: Green-lipped mussel
Normalized name: New Zealand green mussel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green-lipped mussel extract (3,000 mg/day)
Study: 22821424
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (3,000 mg/day)
Study: 16521117
Drug: Pycnogenol 30
Normalized name: Pycnogenol 30 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol 30 mg/day
Study: 1837550
Drug: Prophylactic teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic teicoplanin (one single bolus intravenous injection before catheter insertion)
Study: 6124424
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tofisopam
Study: 6124424
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tofisopam
Study: 31753032
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy (nine sessions, around 60 min each, delivered weekly)
Study: 31753032
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (routine care)
Study: 18448211
Drug: Live, oral
Normalized name: typhoid vaccine, live, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, oral ADV‐4 and ADV‐7 vaccines administered in a single dose to 30 subjects.
Study: 18448211
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to 28 subjects.
Study: 17285717
Drug: Silver nitrate
Normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver nitrate ointment
Study: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRN) administered by a 1-h i.v. infusion at doses of 20, 24, or 29 mg/m2 daily for 5 consecutive days for 2 weeks.
Study: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRN) at doses of 20, 24, and 29 mg/m2.
Study: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRN) after dose 1.
Study: 10741701
Drug: Protracted schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted schedule of administration of Irinotecan (IRN).
Study: 1801155
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of amocarzine once daily (12 patients)
Study: 1801155
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of amocarzine twice daily (59 patients)
Study: 30309839
Drug: Lycopene capsule
Normalized name: Antioxidant Super with Lutein and Lycopene Capsule
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lycopene capsule (15 mg)
Study: 30309839
Drug: Active capsule
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active capsule group (EGCG 600 mg)
Study: 25297016
Drug: Idalopirdine 90
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idalopirdine 90 mg/day (30 mg thrice daily)
Study: 19320533
Drug: Galantamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine treatment for 6 months
Study: 17462043
Drug: Bran supplement
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran supplement with planned nursing interventions
Study: 16353060
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg) with Indapamide (1.25 mg) (Noliprel forte)
Study: 16353060
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) with Hydrochlorothiazide (25 mg) (Capozide)
Study: 11955727
Drug: Beta-interferon (Betaseron)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-interferon (Betaseron) 16 x 10(6) IU by i.v. bolus 3 days a week on Weeks 1, 3, and 5, given 30 minutes before radiation therapy.
Study: 11955727
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone, 2 Gy per fraction, 5 days a week, for a total of 60 Gy over 6 weeks.
Study: 17163255
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g
Study: 9708687
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g plus codeine 60 mg
Study: 2281374
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment group
Study: 28368909
Drug: Asacol 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol 2.4 g once daily (QD) for 48 weeks
Study: 28368909
Drug: Asacol 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol 2.4 g three times daily (TID) for 48 weeks
Study: 26409291
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab 0.05%
Study: 16461077
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 20 mg twice daily
Study: 15290743
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg followed by 200 mg bid
Study: 16960941
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg bid
Study: 11387349
Drug: Zoladex and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex and Tamoxifen in combination (ZT)
Study: 8448748
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg, four times daily for 3 months)
Study: 10408635
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12 mg Zn++/day for one month)
Study: 10408635
Drug: HAART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART therapy
Study: 8772215
Drug: Fragmin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (low-molecular-weight heparin) administered subcutaneously at a fixed dose of 120 Anti-Xa IU/kg twice a day for 10 days.
Study: 8772215
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin administered intravenously.
Study: 1965113
Drug: Intranasal NPC
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal NPC 567 (bradykinin antagonist)
Study: 6162471
Drug: L-Tryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Tryptophan (50 mg/kg) administered twice daily for 7 days
Study: 6162471
Drug: L-Tryptophan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Tryptophan (50 mg/kg) administered either acutely or chronically
Study: 6321356
Drug: Cefotaxime (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1-2 g b.i.d.)
Study: 6321356
Drug: Ceftizoxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (2 g b.i.d.)
Study: 6321356
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g u.i.d.)
Study: 24643203
Drug: Rotigotine 8
Normalized name: ROTIGOTINE 8MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 8 mg/24 h
Study: 24643203
Drug: Rotigotine 8
Normalized name: ROTIGOTINE 8MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 8 mg/24 h vs Placebo
Study: 20811078
Drug: Plyometric training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plyometric training (6 weeks, 3 times weekly)
Study: 17635939
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) users in intervention group
Study: 12087018
Drug: IA-2 antibody
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-2 antibody positive, GAD antibody negative group
Study: 2140735
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the supine position
Study: 2140735
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the seated position
Study: 2140735
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion in both positions
Study: 547544
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg 17 beta‐estradiol or 250 mg estriol
Study: 547544
Drug: gel only
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel only (control group)
Study: 26874388
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical assessment (blind therapy group)
Study: 22773769
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen replacement therapy (ERT) using Evorel patches